An Examination of Healthcare Provider Costs Associated with Paper-Based Consent

Author(s)

Houten R1, Hussain MI2, Ainsworth N1, Rao C3, Lameirinhas C2, Martin A1, St John E4
1QC Medica, Liverpool, UK, 2Research and Innovation, Portsmouth Hospitals University NHS Trust, Portsmouth, UK, 3North Cumbria Integrated Care NHS Foundation Trust, North Cumbria, UK, 4Portsmouth Hospitals University NHS Trust, Portsmouth, UK

OBJECTIVES: The standard paper consent (PC) pathway can be associated with missing information, error, and inadequate patient comprehension. Digital consent (DC) presents an alternative approach to address this unmet need. However, limited research has been conducted to examine costs associated with paper-based consent forms.

METHODS: A micro-costing study was conducted from the UK NHS perspective. Multi-stakeholder involvement (interviews with clinicians and non-clinicians) helped to better understand how the PC pathway varies by department and hospital setting. First, necessary process steps and resources used were identified. Second, time required for each process step was simulated. Third, resources were quantified by calculating labour, purchasing and overhead costs. Lastly a model with different scenarios was constructed to calculate the cost per patient per form. OWSA analysis was performed to identify the key cost drivers and scenario analyses explored aspects such as litigation and digitalisation already in place. A time trial is underway to estimate if there is any variation in consultation time between PC and DC.

RESULTS: Preliminary results show, in a representative department with 110 consenting procedures per month, the cost per consent prior to the day of surgery obtained using paper forms is approximately £2.01 per form. The ordering or printing of paper consent forms, and the transportation of forms to storage and back to clinic are process steps that would not be necessary with DC. OWSA indicates however that if consultation time varies between paper consent and DC this would be the biggest driver of a cost difference. Preventing a single litigation claim with a primary cause of ‘fail to warn – informed consent’ could save £202,735.

CONCLUSIONS: PC pathway presents a non-negligible cost to the UK NHS. Future comparative analyses are needed to inform net cost and consequence impact associated with adoption of DC.

Conference/Value in Health Info

2023-05, ISPOR 2023, Boston, MA, USA

Value in Health, Volume 26, Issue 6, S2 (June 2023)

Code

EE561

Topic

Economic Evaluation, Health Technology Assessment

Topic Subcategory

Cost-comparison, Effectiveness, Utility, Benefit Analysis, Systems & Structure

Disease

Oncology, Surgery

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×